[Thrombolytic therapy of venous thromboses].
Heinz
M
M
I. Medizinische Klinik, Klinikum rechts der Isar der Technischen Universität München.
Theiss
W
W
D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D010960:Plasminogen Activators / Q000009:adverse effects / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000517:prevention & control; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000379:methods*; D013924:Thrombophlebitis / Q000188:drug therapy*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010960:Plasminogen Activators
Lysetherapie venöser Thrombosen.